Mentored Patient-Oriented Research Career Development Award with Emphasis on the Application of Genomic or Proteomic Technologies (K23)

The summary for the Mentored Patient-Oriented Research Career Development Award with Emphasis on the Application of Genomic or Proteomic Technologies (K23) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mentored Patient-Oriented Research Career Development Award with Emphasis on the Application of Genomic or Proteomic Technologies (K23): The purpose of the Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of clinicians who intend to engage in patient-oriented research that involves the application of the knowledge, tools, technologies and approaches of genomics and proteomics to the study of diseases in an effort to develop effective therapeutic interventions. This award will provide support for three to five years of supervised study and research for clinically trained professionals who plan to become independent, productive clinical investigators focusing on patient-oriented research. This K23 award has several important features: (1) it requires an integrated clinical-laboratory research project that directly involves patients affected by the disease being studied so that awardees can develop skills in both clinical research and basic science, i.e. bench-to-bedside research; (2) it emphasizes career development and a research program that focuses on developing effective therapeutic interventions; projects that involve pre-therapeutic research will also be considered if the applicant can make a strong case that the knowledge gained from the study will provide a clear pathway toward the development of therapeutic interventions; and (3) it requires significant utilization of genomic and proteomic tools and technologies in the research project. NHGRI: This initiative is consistent with the NHGRI's new vision for the future of genomics research (http://www.genome.gov/11006873) which includes translating the information and resources generated by the Human Genome Project into medical value and is responsive to the recommendations of the NIH Director's panel on Clinical Research (http://www.nih.gov/news/crp/97report/) and the Institute of Medicine's Committee on Addressing Career paths for Clinical Research (http://www.nap.edu/books/0309048907/html/). ORD: Under the Rare Diseases Act of 2002, the office has a legislative mandate to support training in clinical research in rare diseases. NIDA: The institute is interested in the application of genomic and proteomic tools and technologies in pursuit of therapeutic interventions in drug addiction and drug abuse. The NHGRI's Division of Intramural Research in Bethesda, MD, has a companion program, Physician Scientist Development Program, for clinicians who wish to conduct their research at the National Institutes of Health. To learn more about this program, please visit this website: http://www.nhgri.nih.gov/Intramural_research/PSDP/index.html. Individuals with a clinical degree who are interested in further career development in biomedical research that is not patient-oriented, should refer to the NIH-wide Mentored Clinical Scientist Career Development (K08) Award (see http://grants.nih.gov/training/careerdevelopmentawards.htm on the NIH website for details). Individuals who are interested in patient-oriented research and wish to 1) study the mechanisms of human disease, 2) conduct clinical trials, 3) develop new technologies, or 4) develop therapeutic interventions that do not use genomic or proteomic technologies should refer to the Mentored Patient- Oriented Research Career Development (K23) Award (see http://grants.nih.gov/grants/guide/PA-files/PA-00-004.html).